Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

VOLUNTARY ANNOUNCEMENT FIRST PATIENT ENROLLED IN THE PHASE III CLINICAL TRIAL OF OT-1001 (ZERVIATE) IN CHINA

This announcement is made by Ocumension Therapeutics (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to keep the shareholders of the Company and potential investors informed of the latest business updates of the Group.

The board of directors of Company (the "**Board**") is pleased to announce that the first patient has been successfully enrolled and dosed in the phase III clinical trial of one of the Group's key products, OT-1001 (ZERVIATE), a potent and highly selective histamine-1 receptor antagonist with anti-allergic properties, on December 29, 2020 in China.

OT-1001 (ZERVIATE) was developed by Nicox Ophthalmics, Inc. (together with its subsidiaries and affiliates, "**Nicox**"). It is the first and only topical ophthalmic formulation of the antihistamine cetirizine hydrochloride approved by the United States Food and Drug Administration (the "**FDA**") to treat ocular itching associated with allergic conjunctivitis. Studies have shown that OT-1001 has better effectiveness and safety compared to existing antihistamine therapeutic agents. OT-1001 has a rapid onset of action, and the effect is able to last for at least 8 hours after administration. OT-1001 covers a wide range of patients. In addition to treating adult patients, it is the only ophthalmic antihistamine approved by the FDA for treating pediatric patients of two years and older, which is able to meet the current clinical needs of treating pediatric patients with allergic conjunctivitis. The Group obtained an exclusive license from Nicox to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell (or otherwise commercialize) OT-1001 (ZERVIATE) in the Greater China region in March 2019, and extended the exclusive rights to 11 countries in Southeast Asia in March 2020.

The phase III clinical trial of OT-1001 is designed as a randomized, observer-masked, positive control, multi-center parallel clinical trial evaluating the safety and efficacy of the cetirizine hydrochloride ophthalmic solution of 0.24% concentration for Chinese patients with allergic conjunctivitis, which is expected to enroll approximately 296 patients at approximately 15 clinical centers.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will ultimately commercialize OT-1001 (ZERVIATE) successfully. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board of
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Executive Director

Hong Kong, December 29, 2020

As of the date of this announcement, the Board comprises Dr. Lian Yong CHEN, Mr. Ye LIU, Dr. Zhaopeng HU and Dr. Wei LI as executive directors, Mr. Yanling CAO and Mr. Lefei SUN as non-executive directors, and Mr. Ting Yuk Anthony WU, Mr. Lianming HE, and Mr. Yiran HUANG as independent non-executive directors.